Navigation Links
Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
Date:10/26/2007

TORONTO, Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition") (NASDAQ: TTHI, TSX: TTH) announced the receipt of US$7.5 million representing the second half of the US$15 million upfront payment under the Company's global collaboration agreement with a subsidiary of Elan Corporation, plc ("Elan") (NYSE: ELN) for the Alzheimer's disease drug candidate ELND-005/AZD-103.

ELND-005/AZD-103 has completed Phase I clinical trials and the drug candidate appears to be safe and well tolerated at all doses and dosing regimes examined in approximately 110 subjects. The drug candidate was also shown to be orally bioavailable, cross the blood brain barrier, and achieve levels in the human brain and CSF that were shown to be effective in animal models for Alzheimer's disease.

Transition and its collaborator Elan remain on track to commence a Phase II clinical trial by the end of 2007 or early 2008.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease and regenerative therapies E1-I.N.T.TM and GLP1-I.N.T.TM for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. Infant receives first bloodless liver transplant
9. British MPs Say Prostate Cancer Receives Low Priority in the NHS
10. Fifth US Patient Receives Artificial Heart
11. Northfield Labs Receives FDA Comments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... continues developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices ... the first ANSI-approved GMP standard for dietary supplements this spring, is hiring ...
(Date:3/29/2017)... ... ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: Buying, Selling ... the webinar will also be made available following its live presentation. The webinar is ... popular targets for healthcare investors. This highly fragmented sector bounced back in 2016, as ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (SOGO™), a specialized continuing medical education conference for clinicians who manage some of ... Square, New York. , The program will be led by co- chairs ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Research and Markets has announced the ... 2023" report to their offering. ... The ablation device global market is expected ... by 2023. Ablation is the minimally invasive therapeutic ... cancerous or diseased tissue removal, to the removal of abnormally conducting ...
(Date:3/29/2017)... 29, 2017  NuVasive, Inc. (NASDAQ: NUVA), a ... surgery with minimally disruptive, procedurally-integrated solutions, today announced ... of the CoRoent® Small Interbody™ System indicated for ... the cervical spine. This marks the first U.S. ... at up to four contiguous levels. ...
(Date:3/29/2017)... USA, March 29, 2017 Stryker announced today ... by People magazine, in partnership with Great Place to ... on the list. This list highlights the top U.S. ... in business while also demonstrating respect, compassion and concern ... To determine the companies on the list, ...
Breaking Medicine Technology: